Drug Trial Radar · NCT03228862
Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults
Last checked: Nov 20, 2026Latest source record: Jul 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
360
Actual
Start
May 1, 2017
Primary completion
Feb 1, 2018
Study completion Feb 1, 2018
Sponsor
- Lead sponsor
- Chulalongkorn UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the optimal initial and maintenance doses of vitamin D2 supplementation for the treatment of vitamin D insufficiency in Thai adults, and to determine the prevalence of and risk factors for hypovitaminosis D among Thai adults.
Conditions
- Vitamin D2 Supplementation in Vitamin D Insufficiency
Interventions
ErgocalciferolDrug
Ergocalciferol 40000, 60000 and 80000 once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- serum 25OHD phase 1Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chulalongkorn Univerity and King Chulalongkorn Memorial Hospital
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.